Biologic medicines have transformed treatment for numerous chronic and life-threatening conditions such as cancer, ...
The Institute of Chemical Technology, Mumbai, in collaboration with the Mumbai Biocluster, successfully hosted the 5th Annual ...
The second part of our conversation with Craig Burton, MBA, executive director of the Biosimilars Council, a trade and ...
The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has ...
We spoke recently with Craig Burton, MBA, executive director of the Biosimilars Council, a trade and lobbying group for the ...
Biocon aims to grow through new product launches in generics and biosimilars, bolstered by the Viatris acquisition. This ...
Biocon is set for major growth in the next 2-3 years, propelled by new generics and biosimilars. The Viatris acquisition ...
After registering a net profit of Rs 25.1 crore in Q3FY25 and consolidated revenues growing by 7 per cent on a like-for-like ...
CHMP Adopts Positive Opinion for Aflibercept, Pegfilgrastim Biosimilars: On January 30, 2025, the European Medicines Agency (EMA) Committee ...
Itolizumab demonstrated clinical efficacy after 12 weeks of treatment, achieving a clinical remission rate of 23.3% compared to 20.0% for adalimumab and 10.0% ...
Biosimilar Pipeline Analysis Market BURLINGAME, CA, UNITED STATES, February 6, 2025 /EINPresswire / -- The global Biosimilar Pip ...
WEXFORD, Pa., Feb. 6, 2025 /PRNewswire/ -- COEPTIS, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a pioneering technology company dedicated to advancing cutting-edge technologies and artificial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback